Lonza Group and Patheon extend exclusivity and due diligence period

NewsGuard 100/100 Score

The Special Committee of Independent Directors of Patheon Inc. (TSX:PTI) and Lonza Group AG (SIX:LONN) today announced the extension until October 15, 2009 of the exclusivity and due diligence period to allow for continued discussions regarding the previously announced non-binding proposal to acquire all of the outstanding restricted voting shares of the Company at a price of US$3.55 per share as well as other possible strategic transactions.

The extension allows Lonza to continue to conduct its related confirmatory due diligence and is in accordance with the terms of the existing confidentiality and standstill agreement between Lonza and Patheon announced on August 21, 2009. Other terms remain unchanged, including that Patheon will not negotiate an acquisition transaction with any other party but can respond to an unsolicited acquisition proposal, subject to certain restrictions.

The Lonza proposal does not commit either party to complete any transaction. The transactions contemplated by the Lonza proposal remain subject to Lonza being satisfied with the completion of its confirmatory due diligence, the parties entering into definitive documentation, and the approval of each party's Board of Directors. There can be no assurance that any such transaction will be completed or as to the terms of any such transaction.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.